Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P17643

UPID:
TYRP1_HUMAN

ALTERNATIVE NAMES:
Catalase B; Glycoprotein 75; Melanoma antigen gp75; Tyrosinase-related protein 1

ALTERNATIVE UPACC:
P17643; P78468; P78469; Q13721; Q15679

BACKGROUND:
The enzyme 5,6-dihydroxyindole-2-carboxylic acid oxidase, also referred to as Tyrosinase-related protein 1, is integral to the melanin synthesis pathway. It specifically oxidizes DHICA in the presence of Cu(2+) ions, a step vital for the proper pigmentation of the skin, hair, and eyes. This enzyme's function highlights its importance in the regulation of melanin type, contributing to diverse human pigmentation.

THERAPEUTIC SIGNIFICANCE:
Linked to the genetic condition Albinism, oculocutaneous, 3, which manifests as a moderate reduction in pigment, the enzyme's study offers insights into novel treatment avenues. Exploring the enzyme's mechanism could lead to breakthroughs in managing and treating pigment-related abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.